Bobak R. Azamian, who serves as President, Chief Executive Officer and Chair of the Board at Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), executed three stock-sale transactions between March 17 and March 19, 2026, disposing of a combined 34,603 shares of the company’s common stock for approximately $2.36 million, according to a Form 4 filed with the Securities and Exchange Commission.
The Form 4 details the individual transactions: on March 17 Azamian sold 10,972 shares at $69.42 per share; on March 18 he sold 11,667 shares at $68.71 per share; and on March 19 he sold 11,964 shares at $67.00 per share. The filing states the sales were made to satisfy tax withholding obligations associated with the vesting and settlement of Restricted Stock Units and were mandated by the company.
After completing these sales, Azamian directly holds 33,421 shares of Tarsus Pharmaceuticals common stock. In addition to the direct holdings, he has indirect ownership of 857,991 shares through the Bobak Azamian Living Trust, which was established April 16, 2018.
The company’s shares were trading at $66.75 at the time of the report, a price that implies a market capitalization of roughly $2.85 billion. InvestingPro’s analysis, as cited in the filing materials, lists TARS among the platform’s most undervalued stocks and flags the availability of a comprehensive Pro Research Report covering TARS and more than 1,400 U.S. equities for investors seeking additional detail.
Recent operational and financial context
In related corporate disclosures, Tarsus Pharmaceuticals reported solid financial performance for the fourth quarter of 2025. Net product sales reached $151.7 million for the quarter and $451.4 million for the full year, a performance the company attributed to strength in its lead product, XDEMVY. The quarter and year figures indicate a significant uptick in revenue and profitability versus prior periods, per the company’s announcement.
Despite the strong reported results, the company’s shares experienced a modest decline in aftermarket trading, suggesting a measured investor response. Analysts have not publicly issued any updates in the filing on upgrades or downgrades following the earnings release.
What the filing notes and what remains unchanged
- The securities filing explicitly links the sales to tax-withholding requirements tied to RSU vesting and states the transaction was mandated by the company.
- Azamian’s combined direct and indirect holdings remain substantial, with the majority held indirectly through the living trust.
- Public commentary from analysts on rating changes has not been recorded in the filing following the earnings announcement.
These items provide a factual snapshot of insider activity and recent company performance without offering perspective on longer-term strategic intent or forecasting future share-price movement.
Investor resources
Investors seeking further analysis can reference the InvestingPro Pro Research Report for TARS and the platform’s broader coverage of U.S. equities. The filing and the company’s reported results supply the core public information on which those reports and any subsequent analyst coverage would be based.
All transaction details and ownership figures cited here derive from the company’s SEC Form 4 and the company’s reported quarterly and full-year product sales disclosures.